These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38531621)

  • 1. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
    Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.
    Mease PJ; Ferrante SA; Shiff NJ; Fitzgerald TP; Chakravarty SD; Walsh JA
    Adv Ther; 2024 Dec; ():. PubMed ID: 39621228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
    Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for nail psoriasis.
    de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD007633. PubMed ID: 23440816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of enthesitis with severity of psoriasis in psoriatic arthritis: an observational study.
    Grazio S; Šitum M; Grubišić F; Kavanagh HS; Vajdić ID; Krstanović K; Blajić I
    Rheumatol Int; 2024 Dec; 44(12):2891-2896. PubMed ID: 39402163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
    Coates LC; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Orbai AM; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Merola JF
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Maksymowych WP; Lagunes-Galindo I; Bu X; Wung P; Kato K; Shmagel A; Deodhar A
    Arthritis Res Ther; 2024 Nov; 26(1):197. PubMed ID: 39533349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME; Mease PJ; Merola JF; Tillett W; Goldammer N; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39313302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial.
    Malone A; Kowalski MM; Helliwell J; Lynggaard Boll S; Rovsing H; Moriat K; Castillo Mondragón A; Li Y; Prener Miller C; Reinstrup Bihlet A; Dobek C; Peck V; Wilmink M; Simon LS; Conaghan PG
    Lancet Rheumatol; 2024 Dec; 6(12):e860-e870. PubMed ID: 39401503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical component of SF-36 is associated with measures of disease activity in patients with psoriatic arthritis: a real-life study from a tertiary referral centre.
    Doko Vajdić I; Cvijetić Avdagić S; Grubišić F; Doko Šarić K; Vlak T; Skala Kavanagh H; Šošo D; Grazio S
    Rheumatol Int; 2024 Dec; 44(12):2897-2904. PubMed ID: 39384567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Extra-Musculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.
    Poddubnyy D; Parikh B; Elewaut D; Navarro-Compán V; Siebert S; Paley M; Coombs D; Lagunes I; Biljan A; Nakasato P; Wung P; Lubrano E
    Arthritis Rheumatol; 2024 Dec; ():. PubMed ID: 39624020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdisciplinary approach to patients with psoriatic arthritis: a prospective, single-center cohort study.
    Gross G; Lull C; von Ahnen JA; Blauth M; Schwaan J; Olsavszky V; Schmieder A; Leipe J
    Ther Adv Chronic Dis; 2024; 15():20406223241293698. PubMed ID: 39619167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidate Biomarkers for Response to Treatment in Psoriatic Disease.
    Offenheim R; Cruz-Correa OF; Ganatra D; Gladman DD
    J Rheumatol; 2024 Dec; 51(12):1176-1186. PubMed ID: 39218451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study.
    Rattanakaemakorn P; Chevaisrakul P; Wongpraparut C; Chiowchanwisawakit P; Tovanabutra N; Tantiwong P; Amornpinyo W; Chakkavittumrong P; Hanvivadhanakul P; Chaiamnuay S; Laodheerasiri S; Pattamadilok B; Choonhakarn C; Mahakkanukrauh A; Aiewruengsurat D; Sangmala S; Pretikul N; Sumethkul K; Satpanich P; Boonsiri M; Sangob N; Asawanonda P;
    Dermatol Ther (Heidelb); 2024 Dec; 14(12):3229-3241. PubMed ID: 39505788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.